DK563487D0 - Stabil farmaceutisk komposition af rekombinant beta-interferon - Google Patents
Stabil farmaceutisk komposition af rekombinant beta-interferonInfo
- Publication number
- DK563487D0 DK563487D0 DK563487A DK563487A DK563487D0 DK 563487 D0 DK563487 D0 DK 563487D0 DK 563487 A DK563487 A DK 563487A DK 563487 A DK563487 A DK 563487A DK 563487 D0 DK563487 D0 DK 563487D0
- Authority
- DK
- Denmark
- Prior art keywords
- stable pharmaceutical
- pharmaceutical composition
- beta interferon
- recombinant beta
- ionic polymeric
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000003996 Interferon-beta Human genes 0.000 title 1
- 108090000467 Interferon-beta Proteins 0.000 title 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
- 239000003599 detergent Substances 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- 239000003381 stabilizer Substances 0.000 abstract 2
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 230000003381 solubilizing effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92342386A | 1986-10-27 | 1986-10-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK563487D0 true DK563487D0 (da) | 1987-10-27 |
| DK563487A DK563487A (da) | 1988-04-28 |
Family
ID=25448670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK563487A DK563487A (da) | 1986-10-27 | 1987-10-27 | Stabil farmaceutisk komposition af rekombinant beta-interferon |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0270799B1 (da) |
| JP (1) | JPS63179833A (da) |
| AT (1) | ATE111744T1 (da) |
| AU (2) | AU8019187A (da) |
| CA (1) | CA1294215C (da) |
| DE (1) | DE3750574T2 (da) |
| DK (1) | DK563487A (da) |
| FI (1) | FI95002C (da) |
| NO (1) | NO175704C (da) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5183746A (en) * | 1986-10-27 | 1993-02-02 | Schering Aktiengesellschaft | Formulation processes for pharmaceutical compositions of recombinant β- |
| US4961969A (en) * | 1987-05-11 | 1990-10-09 | Cetus Corporation | Process for recovering microbially produced interferon-β |
| US5151265A (en) * | 1987-11-03 | 1992-09-29 | Genentech, Inc. | Gamma interferon formulation |
| US5004605A (en) * | 1987-12-10 | 1991-04-02 | Cetus Corporation | Low pH pharmaceutical compositions of recombinant β-interferon |
| IL89662A (en) * | 1989-03-19 | 1997-11-20 | Interpharm Lab Ltd Kiryat Weiz | Pharmaceutical compositions comprising interferon-beta |
| US6586222B1 (en) | 1989-08-16 | 2003-07-01 | Chiron Corporation | Recombinant PR-3 and compositions thereof |
| US5998378A (en) * | 1989-08-16 | 1999-12-07 | Chiron Corporation | Compositions for the inhibition of TNF hormone formation and uses thereof |
| US5843693A (en) * | 1989-08-16 | 1998-12-01 | Chiron Corporation | Assay method for screening for inhibitors of proTNF conversion |
| US6063764A (en) * | 1992-06-01 | 2000-05-16 | Washington University & Chiron Corp. | Method for using lipoprotein associated coagulation inhibitor to treat sepsis |
| US20030171292A1 (en) | 1992-06-01 | 2003-09-11 | Creasey Abla A. | Method for using lipoprotein associated coagulation inhibitor to treat sepsis |
| CA2147466A1 (en) * | 1992-10-20 | 1994-04-28 | Just P. J. Brakenhoff | Interleukin-6 receptor antagonists |
| CA2185162A1 (en) | 1994-03-07 | 1995-09-14 | Robert F. Halenback (Deceased) | Compositions for the inhibition of tnf formation and uses thereof |
| IT1272252B (it) | 1994-05-16 | 1997-06-16 | Applied Research Systems | Formulazioni liquide di interferone beta |
| US5556771A (en) * | 1995-02-10 | 1996-09-17 | Gen-Probe Incorporated | Stabilized compositions of reverse transcriptase and RNA polymerase for nucleic acid amplification |
| GB9506051D0 (en) | 1995-03-24 | 1995-05-10 | Univ Singapore | Gene expression |
| US20030190307A1 (en) | 1996-12-24 | 2003-10-09 | Biogen, Inc. | Stable liquid interferon formulations |
| JP4293497B2 (ja) | 1997-09-23 | 2009-07-08 | レントシュレール ビオテクノロジー ゲー・エム・ベー・ハー | インターフェロン−β液状組成物 |
| US6465425B1 (en) | 2000-02-10 | 2002-10-15 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins |
| US7544354B2 (en) | 2000-10-27 | 2009-06-09 | Novartis Vaccines And Diagnostics | Methods of protein purification and recovery |
| JP4129178B2 (ja) | 2000-11-07 | 2008-08-06 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 安定化されたインターフェロン組成物 |
| US7101693B2 (en) | 2001-09-07 | 2006-09-05 | Brigham Young University | Plasticized hydrophilic glasses for improved stabilization of biological agents |
| CA2463655A1 (en) | 2001-10-15 | 2003-04-24 | Chiron Corporation | Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi) |
| AU2004287480B2 (en) | 2003-11-04 | 2011-09-15 | Novartis Vaccines And Diagnostics, Inc. | Use of antagonist anti-CD40 antibodies for treatment of chronic lymphocytic leukemia |
| ATE474599T1 (de) | 2003-11-04 | 2010-08-15 | Novartis Vaccines & Diagnostic | Verwendung von antagonisten-anti-cd40- monoklonalen antikörpern zur behandlung von multiplem myelom |
| PT1694360E (pt) | 2003-11-04 | 2010-12-13 | Novartis Vaccines & Diagnostic | Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento de doenças auto-imunes e inflamatórias e da rejeição ao transplante de orgãos |
| PT1684869E (pt) | 2003-11-04 | 2011-09-16 | Novartis Vaccines & Diagnostic | Métodos de terapêutica para cancros relacionados com células b |
| PT1680141E (pt) | 2003-11-04 | 2010-12-20 | Novartis Vaccines & Diagnostic | Métodos terapêuticos para tumores sólidos que expressam o antigénio de superfície celular cd40 |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| WO2012075111A1 (en) | 2010-11-30 | 2012-06-07 | Novartis Ag | Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers |
| AU2011335551B2 (en) | 2010-12-02 | 2016-10-06 | Bionor Immuno As | Peptide scaffold design |
| CA2821995C (en) | 2011-01-06 | 2019-02-12 | Bionor Immuno As | Monomeric and multimeric peptides immunogenic against hiv |
| WO2013182661A1 (en) | 2012-06-06 | 2013-12-12 | Bionor Immuno As | Peptides derived from viral proteins for use as immunogens and dosage reactants |
| UA105278C2 (ru) | 2012-09-06 | 2014-04-25 | Інститут Біології Клітини Нан України | Способ получения каталитически активных антител (абзимов) с сиалидазной активностью |
| EP3718467A1 (en) | 2013-04-23 | 2020-10-07 | Cedars-Sinai Medical Center | Systems and methods for recording simultaneously visible light image and infrared light image from fluorophores |
| CA2935404A1 (en) | 2014-01-17 | 2015-07-23 | Cedars-Sinai Medical Center | Receptor targeting constructs and uses thereof |
| US10029997B2 (en) | 2014-06-12 | 2018-07-24 | Cedars-Sinai Medical Center | Compositions and methods for treating cancers |
| US11786469B2 (en) | 2014-07-22 | 2023-10-17 | Cheolhee WON | Silica nanoparticle composition for delivering bioactive material or protein such as a human proteasome |
| EP3215186A4 (en) | 2014-11-04 | 2018-10-24 | University of Southern California | COMPOSITIONS AND METHODS FOR TREATING HIF-1alpha OVER-EXPRESSING CANCERS |
| US10441644B2 (en) | 2015-05-05 | 2019-10-15 | The Regents Of The University Of California | H3.3 CTL peptides and uses thereof |
| AU2016258984B2 (en) | 2015-05-05 | 2020-11-19 | The Regents Of The University Of California | H3.3 CTL peptides and uses thereof |
| EP3345000B1 (en) | 2015-08-31 | 2022-08-31 | Cedars-Sinai Medical Center | Novel blood cell biomarker for late onset alzheimer's disease |
| KR20180103817A (ko) | 2016-02-09 | 2018-09-19 | 오토텔릭 엘엘씨 | 암을 치료하기 위한 조성물과 방법 |
| KR20180103816A (ko) | 2016-02-09 | 2018-09-19 | 오토텔릭 엘엘씨 | 췌장암을 치료하기 위한 조성물과 방법 |
| FI126979B (en) * | 2016-02-29 | 2017-09-15 | Faron Pharmaceuticals Oy | Lyophilized pharmaceutical formulation and use thereof |
| WO2018143787A1 (ko) | 2017-02-06 | 2018-08-09 | 주식회사 레모넥스 | 생리활성물질 전달체 |
| CA3052561C (en) | 2017-02-06 | 2023-02-14 | Lemonex Inc. | Physiologically active substance carrier |
| EP3658139A4 (en) | 2017-07-25 | 2021-04-07 | Cedars-Sinai Medical Center | Methods for treating liver diseases |
| AU2018321950A1 (en) | 2017-08-22 | 2020-03-19 | Cedars-Sinai Medical Center | Compositions and methods for treating cancer |
| US11530132B2 (en) | 2017-09-05 | 2022-12-20 | Lemonex Inc. | Composition comprising porous silica particles carrying a cell fate modulating factor |
| US11690799B2 (en) | 2018-04-19 | 2023-07-04 | Lts Lohmann Therapie-Systeme Ag | Microneedle system for applying interferon |
| EP3781127B1 (de) * | 2018-04-19 | 2022-01-12 | LTS LOHMANN Therapie-Systeme AG | Mikronadelsystem zur applikation von interferon |
| EP3877412A4 (en) | 2018-11-08 | 2022-08-10 | Cedars-Sinai Medical Center | USE OF CLAZAKIZUMAB TO DESENSITIZE AND IMPROVE KIDNEY TRANSPLANTATION IN HLA-SENSITIZED PATIENTS |
| US20220073605A1 (en) | 2018-12-20 | 2022-03-10 | Cedars-Sinai Medical Center | Clazakizumab in the treatment of chronic antibody-mediated rejection of organ transplant |
| WO2021160887A1 (en) | 2020-02-14 | 2021-08-19 | Immunor As | Corona virus vaccine |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55102519A (en) * | 1979-01-31 | 1980-08-05 | Green Cross Corp:The | Stabilization of interferon |
| CA1190148A (en) * | 1981-10-13 | 1985-07-09 | Samuel S. Asculai | Interferon-containing compositions |
| JPS5910524A (ja) * | 1982-07-08 | 1984-01-20 | Toray Ind Inc | インタ−フエロン組成物およびその製造法 |
| US4992271A (en) * | 1982-09-23 | 1991-02-12 | Cetus Corporation | Formulation for lipophilic IL-2 proteins |
| US4462940A (en) * | 1982-09-23 | 1984-07-31 | Cetus Corporation | Process for the recovery of human β-interferon-like polypeptides |
| ATE52693T1 (de) * | 1982-10-25 | 1990-06-15 | Genentech Inc | Synergistische humaninterferonaktivitaet. |
| EP0150067A3 (en) * | 1984-01-23 | 1986-12-30 | Takeda Chemical Industries, Ltd. | Stable composition of gamma-interferon |
| US4680175A (en) * | 1984-02-07 | 1987-07-14 | Interferon Sciences, Inc. | Interferon administration vehicles |
| US4606917A (en) * | 1984-10-03 | 1986-08-19 | Syntex (U.S.A) Inc. | Synergistic antiviral composition |
| JPS61277633A (ja) * | 1985-05-31 | 1986-12-08 | Toray Ind Inc | インタ−フエロン組成物 |
-
1987
- 1987-10-16 CA CA000549489A patent/CA1294215C/en not_active Expired - Lifetime
- 1987-10-26 FI FI874706A patent/FI95002C/fi not_active IP Right Cessation
- 1987-10-26 DE DE3750574T patent/DE3750574T2/de not_active Expired - Lifetime
- 1987-10-26 EP EP87115693A patent/EP0270799B1/en not_active Expired - Lifetime
- 1987-10-26 AT AT87115693T patent/ATE111744T1/de not_active IP Right Cessation
- 1987-10-26 NO NO874445A patent/NO175704C/no not_active IP Right Cessation
- 1987-10-27 JP JP62271604A patent/JPS63179833A/ja active Pending
- 1987-10-27 AU AU80191/87A patent/AU8019187A/en not_active Abandoned
- 1987-10-27 DK DK563487A patent/DK563487A/da not_active Application Discontinuation
-
1992
- 1992-02-03 AU AU10633/92A patent/AU659127B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| EP0270799A1 (en) | 1988-06-15 |
| FI874706A0 (fi) | 1987-10-26 |
| AU659127B2 (en) | 1995-05-11 |
| NO175704C (no) | 1994-11-23 |
| NO874445L (no) | 1988-04-28 |
| AU8019187A (en) | 1988-04-28 |
| NO874445D0 (no) | 1987-10-26 |
| FI95002C (fi) | 1995-12-11 |
| DK563487A (da) | 1988-04-28 |
| AU1063392A (en) | 1992-03-19 |
| DE3750574T2 (de) | 1995-02-02 |
| EP0270799B1 (en) | 1994-09-21 |
| DE3750574D1 (de) | 1994-10-27 |
| FI874706L (fi) | 1988-04-28 |
| CA1294215C (en) | 1992-01-14 |
| ATE111744T1 (de) | 1994-10-15 |
| FI95002B (fi) | 1995-08-31 |
| NO175704B (no) | 1994-08-15 |
| JPS63179833A (ja) | 1988-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK563487A (da) | Stabil farmaceutisk komposition af rekombinant beta-interferon | |
| ATE74512T1 (de) | Pharmazeutische zusammensetzungen von rekombinanten interleukin-2 und herstellungsverfahren. | |
| KR100656125B1 (ko) | 장기 안정화 제제 | |
| US5766582A (en) | Stable, aqueous alfa interferon solution formulations | |
| ATE106247T1 (de) | Formulierung für rekombinantes beta-interferon, verfahren zur gewinnung und stabilisierung des beta-interferons und dessen verwendung. | |
| ATE66817T1 (de) | Stabile formulierung biologisch aktiver proteine zur parenteralen injektion. | |
| EP0374257B1 (en) | STABLE INTERFERON $g(b) COMPOSITION | |
| DK1381432T3 (da) | HSA-frie interferon-beta-præparater | |
| EE05201B1 (et) | Glkoslitud interferoon-beeta, selle kasutamine ja seda sisaldav farmatseutiline kompositsioon, meetod interferoon-beeta-1a aktiivsuse pikendamiseks ja leiutisekohase valgu valmistamiseks | |
| NL930119I2 (nl) | Farmaceutische en veterinaire preparaten van cysteine-125-verminderde muteïnen van interleukine-2 ende produktie daarvan. | |
| CN1993139B (zh) | 稳定的干扰素液体制剂 | |
| CY1110352T1 (el) | Αντι-ιικος παραγοντας υπο τη μορφη ρινικων σταγονων | |
| DE69518152D1 (de) | Flüssige beta-interferon formulierungen | |
| FI915654A0 (fi) | Somatotropiner med alterneringar i alfahelixregionen 1 och kombinationer med andra mutationer. | |
| FI822331A0 (fi) | Blandningar foer lokal anvaendning pao huden | |
| DK0456153T3 (da) | Galeniske vandige formuleringer af erythopoietin og deres anvendelse |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ATS | Application withdrawn |